JP5646509B2 - (1s,2r)−ミルナシプランの合成方法 - Google Patents
(1s,2r)−ミルナシプランの合成方法 Download PDFInfo
- Publication number
- JP5646509B2 JP5646509B2 JP2011546850A JP2011546850A JP5646509B2 JP 5646509 B2 JP5646509 B2 JP 5646509B2 JP 2011546850 A JP2011546850 A JP 2011546850A JP 2011546850 A JP2011546850 A JP 2011546850A JP 5646509 B2 JP5646509 B2 JP 5646509B2
- Authority
- JP
- Japan
- Prior art keywords
- toluene
- acid
- represented
- phthalimide
- milnacipran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- GJJFMKBJSRMPLA-DZGCQCFKSA-N levomilnacipran Chemical compound C=1C=CC=CC=1[C@]1(C(=O)N(CC)CC)C[C@H]1CN GJJFMKBJSRMPLA-DZGCQCFKSA-N 0.000 title claims description 12
- 238000001308 synthesis method Methods 0.000 title 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 111
- 238000000034 method Methods 0.000 claims description 27
- 239000002904 solvent Substances 0.000 claims description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 21
- 239000012429 reaction media Substances 0.000 claims description 18
- 150000002596 lactones Chemical class 0.000 claims description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 14
- 229910052783 alkali metal Inorganic materials 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 10
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical class C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims description 10
- 150000001340 alkali metals Chemical class 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 7
- 229940011051 isopropyl acetate Drugs 0.000 claims description 7
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- 239000002841 Lewis acid Substances 0.000 claims description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- 150000007517 lewis acids Chemical class 0.000 claims description 6
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 claims description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 6
- 150000003973 alkyl amines Chemical class 0.000 claims description 5
- 238000005660 chlorination reaction Methods 0.000 claims description 5
- 239000013067 intermediate product Substances 0.000 claims description 5
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 5
- XNCDYJFPRPDERF-NQQJLSKUSA-N (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropane-1-carboxamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1[C@]1(C(=O)N(CC)CC)C[C@H]1CN XNCDYJFPRPDERF-NQQJLSKUSA-N 0.000 claims description 4
- RXYPXQSKLGGKOL-UHFFFAOYSA-N 1,4-dimethylpiperazine Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 claims description 4
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 claims description 4
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- BRLQWZUYTZBJKN-VKHMYHEASA-N (-)-Epichlorohydrin Chemical compound ClC[C@H]1CO1 BRLQWZUYTZBJKN-VKHMYHEASA-N 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical group [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
- 238000010306 acid treatment Methods 0.000 claims description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000004312 hexamethylene tetramine Substances 0.000 claims description 2
- 235000010299 hexamethylene tetramine Nutrition 0.000 claims description 2
- 125000005543 phthalimide group Chemical group 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000010908 decantation Methods 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- -1 NaOH or KOH Chemical class 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960000600 milnacipran Drugs 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-GASJEMHNSA-N (2xi)-D-gluco-heptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C(O)=O KWMLJOLKUYYJFJ-GASJEMHNSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- PZZSKDUDPJLOJL-GXTWGEPZSA-N CCN(C([C@@]1([C@H](CO)C1)c1ccccc1)=O)[IH]C Chemical compound CCN(C([C@@]1([C@H](CO)C1)c1ccccc1)=O)[IH]C PZZSKDUDPJLOJL-GXTWGEPZSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 150000002641 lithium Chemical class 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- CETVQRFGPOGIQJ-UHFFFAOYSA-N lithium;hexane Chemical compound [Li+].CCCCC[CH2-] CETVQRFGPOGIQJ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- HCZCGHSBNHRSLG-UHFFFAOYSA-N n,n-disilylmethanamine Chemical compound CN([SiH3])[SiH3] HCZCGHSBNHRSLG-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/16—Preparation of optical isomers
- C07C231/18—Preparation of optical isomers by stereospecific synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
Description
本発明は、(1S,2R)−ミルナシプランの不斉合成法ならびに主要な(1S,2R)鏡像異性型の塩素化中間体に関する。
ミルナシプラン(milnacipran)は、鬱病の処置において推奨されるセロトニン−ノルアドレナリンの再取り込みを阻害する抗鬱薬である(FR2508035号公報)。
(a)フェニルアセトニトリルと、(R)−エピクロルヒドリンとを、アルカリ金属を含有する塩基の存在下で反応後、塩基性処理を行い、次いで酸性処理を行い、下記式(II)で表されるラクトンを得る工程:
(f)前記工程(e)で得られた(1S,2R)−ミルナシプランを好適な溶媒系で、薬学上許容される酸の存在下で塩化する(salification)工程。
この工程は以下の一連の反応に相当する。
[式中、
Mはアルカリ金属、特に、ナトリウム(Na)、カリウム(K)、またはリチウム(Li)を表し、かつ
Rは、水素原子、アルキル(ブチルまたはヘキシルなど)、アルコキシ(ターチオブチルオキシ(tertiobutyloky)、またはNR1 2基を表し、R1は水素原子、アルキル(イソプロピルなど)、またはSi(CH3)3基を表す]。
「アルカリ金属」とは、より詳しくは、ナトリウム、カリウム、およびリチウムを意味する。
この塩素化工程中に塩酸が生じる。この化合物を次の工程の前に除去することが重要である。トルエンなどの溶媒を使用することにより、反応媒体の濃縮によって、その除去が容易となり得る。実際、トルエンを用いると、その沸点が高いために、塩化メチレンなどの溶媒よりもより容易に共蒸発によって塩酸を除去することが可能である。
この工程は有利にはフタルイミドのカリウム塩を用いて行うであろう。この反応は有利には溶媒としてのトルエン中で行うことができる。
フタルイミド誘導体を第一級アミンに加水分解するこの工程は有利には、ヒドラジン、メチルアミンなどのアルキルアミン、またはエタノールアミンなどのヒドロキシアルキルアミンと反応させることにより行われる。
この工程によれば、前工程(e)で得られた(1S,2R)−ミルナシプランを塩化すると同時に結晶化とその後の濾過によって(1S,2R)−ミルナシプランの酸付加塩を精製および単離することが可能である。
-0〜50容量%(体積百分率)、有利には30〜40容量%のトルエン、
-40〜90容量%、有利には50〜80容量%の酢酸イソプロピルおよび
-5〜25容量%、有利には10〜20容量%のイソプロパノール。
28kgのナトリウムアミド(682モル)を400Lのトルエンに懸濁させた後、強い攪拌下で、10Lのトルエンに希釈した85.5kgのフェニルアセトニトリル(729.5モル)を0〜5℃の温度で注ぐ。この反応媒体を10℃で少なくとも1時間攪拌する。20Lのトルエン中、27kgのキラルエピクロルヒドリン(292モル)の溶液を、温度を10℃に維持しながら加える。注ぎ終わったところで、この媒体を少なくとも2時間攪拌する。この反応媒体を、温度を5〜40℃に維持しながら240Lの水溶液に注ぐことによって加水分解を行う。得られた溶液を濃縮した後、115kgの30%ソーダを加え、ニトリル官能基の加水分解を可能とするために、この媒体を95℃まで加熱する。媒体を190Lのトルエンで2回洗浄する。トルエン相を除去し、270Lのトルエンを加えた後に水相を回収し、25%塩酸溶液で1〜2の間のpHまで酸性化する。次に、この媒体を60℃まで少なくとも3時間加熱する。デカンテーションの後、ラクトンを含有するトルエン相を140Lの水で洗浄し、10%炭酸ナトリウム溶液で8〜9の間のpHまで中和し、次いで、再び140Lの水で洗浄する。得られたトルエン相を120Lの容量まで濃縮する(38kgのラクトン(218モル)を含有)。
34kgの塩化アルミニウム(255モル)を240Lのトルエンに懸濁させ、38.3kgのジエチルアミン(523.5モル)を、温度を15〜30℃に維持しながら加える。先に得られたラクトン濃縮物(38kg)を、25℃に維持した媒体に注ぐ。この反応媒体を少なくとも1時間30分攪拌する。沈殿の形成が見られる。
25℃にて強い攪拌下、この濃縮物に24.7kgの塩化チオニル(207モル)を1時間以内に注ぐ。温度を50℃に制限し、この反応媒体を真空濃縮する。62Lのトルエンを2回加えた後にこの濃縮操作を2回繰り返して塩素化アミドの濃縮物を得る。
前工程で得られた塩素化アミド濃縮物を、カリウムフタルイミドの懸濁液(155Lのトルエン中、51.9kgのカリウムフタルイミド(280モル))に注ぎ、この媒体を85℃まで少なくとも3時間加熱する。反応媒体を45℃まで冷却し、130Lの水で2回洗浄する。デカンテーション後、得られたトルエン相は約74kgのフタルイミド−アミド(196.5モル)を含む。
強い攪拌下、92.4kgのエタノールアミン(1513モル)をフタルイミド−アミドのトルエン溶液に導入し、この媒体を82.5℃まで2時間加熱する。冷却し、247Lのトルエンを加えた後、この反応媒体を225Lの塩水20%NaCl水溶液で洗浄する。水相を52Lのトルエンで2回逆抽出した後、トルエン相を合わせ、225Lの塩水20%NaCl溶液で2回洗浄する。デカンテーション後、185Lの水をトルエン相に加え、媒体を25%塩酸で2〜3のpHまで酸性化する。デカンテーション後、酸性有機相を再び74Lの水で抽出する。その後、有機相を除去する。合わせた水相を、20%ソーダ水溶液で12〜13の間の塩基性pHまで戻した後、370Lおよび150Lのトルエンで2回抽出する。合わせた有機相を80Lの水で洗浄した後、濃縮する。
トルエン濃縮物に283Lの酢酸イソプロピルと48.4Lのイソプロパノールを加える。この有機溶液に、30℃でイソプロパノール中5Nの塩酸溶液を3〜4のpHとなるまで注ぐ(約30Lの溶液)。この酸性溶液の導入中、塩酸塩が沈殿し、この媒体を10℃まで冷却し、この温度で少なくとも2時間維持する。この懸濁液を濾過し、56Lの酢酸イソプロピルで3回洗浄する。得られた生成物を70℃で真空乾燥させる。41kgの(1S,2R)−ミルナシプラン塩酸塩(145モル)が得られ、すなわち、キラルエピクロルヒドリンに対して49.6%の収率である。
Claims (12)
- 下記式(I)で表される(1S,2R)−ミルナシプランの薬学上許容される酸付加塩の合成方法であって:
(a)フェニルアセトニトリルと、(R)−エピクロルヒドリンとを、アルカリ金属を含有する塩基の存在下で反応後、塩基性処理を行い、次いで酸性処理を行い、下記式(II)で表されるラクトンを得る工程:
(f)前記工程(e)で得られた(1S,2R)−ミルナシプランを好適な溶媒系で、薬学上許容される酸の存在下で塩化する工程、
ここで、工程(a)〜(e)が同じ単一の溶媒を含んでなる反応媒体中で行われ、該溶媒がトルエンである。 - フタルイミド塩がフタルイミドのカリウム塩である、請求項1に記載の方法。
- 工程(a)〜(d)で得られるいずれの中間生成物も反応媒体から単離されない、請求項1または2に記載の方法。
- 工程(a)〜(e)で得られるいずれの中間生成物も反応媒体から単離されない、請求項3に記載の方法。
- 工程(b)がNHEt2およびルイス酸としてのAlCl3の存在下で行われる、請求項1〜4のいずれか一項に記載の方法。
- 加水分解工程(e)がヒドラジン、アルキルアミン、またはヒドロキシアルキルアミンと反応させることにより行われる、請求項1〜5のいずれか一項に記載の方法。
- アルキルアミンがメチルアミンであり、かつヒドロキシアルキルアミンがエタノールアミンである、請求項6に記載の方法。
- (1S,2R)−ミルナシプラン塩酸塩を得るために塩化工程(f)が塩酸の存在下で行われる、請求項1〜7のいずれか一項に記載の方法。
- 塩化工程(f)がトルエンを含んでなる溶媒系で行われる、請求項1〜8のいずれか一項に記載の方法。
- 溶媒系が、トルエン、酢酸イソプロピル、およびイソプロパノールの混合物である、請求項9に記載の方法。
- 溶媒系が溶媒全量に対して以下の組成を有する、請求項10に記載の方法:
-30〜50容量%のトルエン、
-40〜90容量%の酢酸イソプロピル、および
-5〜25容量%のイソプロパノール。 - 溶媒系が溶媒全量に対して以下の組成を有する、請求項11に記載の方法:
-30〜40容量%のトルエン
-50〜80容量%の酢酸イソプロピル、および
-10〜20容量%のイソプロパノール。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0950552A FR2941454B1 (fr) | 2009-01-29 | 2009-01-29 | Proced de synthese du (1s,2r)-milnacipran |
FR0950552 | 2009-01-29 | ||
PCT/EP2010/051045 WO2010086394A1 (en) | 2009-01-29 | 2010-01-29 | Method for synthesis of (1s, 2r)-milnacipran |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012516307A JP2012516307A (ja) | 2012-07-19 |
JP5646509B2 true JP5646509B2 (ja) | 2014-12-24 |
Family
ID=40920574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011546850A Active JP5646509B2 (ja) | 2009-01-29 | 2010-01-29 | (1s,2r)−ミルナシプランの合成方法 |
Country Status (23)
Country | Link |
---|---|
US (1) | US8604241B2 (ja) |
EP (1) | EP2391599B1 (ja) |
JP (1) | JP5646509B2 (ja) |
KR (1) | KR101719011B1 (ja) |
CN (2) | CN102300840A (ja) |
AR (2) | AR077526A1 (ja) |
AU (1) | AU2010209686B2 (ja) |
BR (1) | BRPI1007404B8 (ja) |
CA (1) | CA2750488C (ja) |
ES (1) | ES2472695T3 (ja) |
FR (1) | FR2941454B1 (ja) |
GE (1) | GEP20135903B (ja) |
IL (1) | IL214241A (ja) |
MA (1) | MA33025B1 (ja) |
MX (1) | MX2011007846A (ja) |
NZ (1) | NZ594291A (ja) |
PL (1) | PL2391599T3 (ja) |
RU (1) | RU2521342C2 (ja) |
TN (1) | TN2011000363A1 (ja) |
TW (1) | TWI455911B (ja) |
UA (1) | UA104884C2 (ja) |
WO (1) | WO2010086394A1 (ja) |
ZA (1) | ZA201105414B (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2944011B1 (fr) * | 2009-04-03 | 2011-05-20 | Pf Medicament | Derives d'aminocyclobutane ou d'aminocyclobutene, leur procede de preparation et leur utilisation a titre de medicaments. |
WO2011158249A1 (en) * | 2010-06-16 | 2011-12-22 | Glenmark Generics Limited | Process for preparation of milnacipran intermediate and its use in preparation of pure milnacipran |
WO2012046247A2 (en) * | 2010-10-06 | 2012-04-12 | Msn Laboratories Limited | Process for the preparation of (±m1r(s), 2srr)l-2-(aminomethyl)-n,n-diethyl-l-phenylcyclopropane carboxamide hydrochloride |
JP5952305B2 (ja) * | 2011-01-24 | 2016-07-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 2,2−ジフルオロ−1−クロロエタンから出発して2,2−ジフルオロエチルアミンを製造する方法 |
EP2814798B1 (en) * | 2012-02-17 | 2019-04-03 | Eisai R&D Management Co., Ltd. | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists |
WO2014009767A1 (en) | 2012-07-07 | 2014-01-16 | Micro Labs Limited | An improved process for the preparation of 1-aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers and salts |
EP2805936A1 (en) | 2013-05-20 | 2014-11-26 | Cosma S.p.A. | Process for preparing levomilnacipran HCL |
WO2014203277A2 (en) * | 2013-06-19 | 2014-12-24 | Msn Laboratories Private Limited | Process for the preparation of (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanearboxamide hydrochloride |
CN103694162B (zh) * | 2014-01-03 | 2015-09-02 | 上海现代制药股份有限公司 | (1s,2r)-1-苯基2-(酞酰亚胺)甲基-n,n-二乙基-环丙甲酰胺的制备方法 |
CN104058992A (zh) * | 2014-06-13 | 2014-09-24 | 上海现代制药股份有限公司 | 左旋米那普仑盐酸盐的晶型 |
CN106795097A (zh) | 2014-10-03 | 2017-05-31 | 普拉克生化公司 | N,n‑二烷基乳酰胺的生产方法 |
CA2966437A1 (en) | 2014-11-04 | 2016-05-12 | Quimica Sintetica, S.A. | Process for the preparation of (1s,2r)-milnacipran |
CN106083638A (zh) * | 2016-07-07 | 2016-11-09 | 佛山市隆信医药科技有限公司 | 一种盐酸左旋米那普仑的制备方法 |
CN111175387B (zh) * | 2018-11-13 | 2022-06-07 | 成都康弘药业集团股份有限公司 | 一种米那普仑异构体的检测方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2508035A1 (fr) | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central |
FR2581059B1 (fr) | 1985-04-25 | 1988-04-22 | Pf Medicament | Procede de preparation du chlorhydrate de phenyl-1 diethyl amino carbonyl-1 aminomethyl-2 cyclopropane (z) |
FR2640972B1 (ja) | 1988-12-28 | 1991-04-19 | Pf Medicament | |
JPH0834765A (ja) * | 1994-02-22 | 1996-02-06 | Asahi Chem Ind Co Ltd | アミノアルキルシクロプロパン誘導体 |
US5621142A (en) | 1994-02-22 | 1997-04-15 | Asahi Kasei Kogyo Kabushiki Kaisha | Aminoalkylcyclopropane derivatives |
WO2005118564A2 (en) | 2004-06-01 | 2005-12-15 | Collegium Pharmaceutical, Inc. | Methods for the synthesis of milnacipran and congeners thereof |
JP4712320B2 (ja) * | 2004-06-16 | 2011-06-29 | 住友化学株式会社 | 2−オキソ−1−フェニル−3−オキサビシクロ[3.1.0]ヘキサンの製造方法 |
JP4418717B2 (ja) * | 2004-06-24 | 2010-02-24 | 住友化学株式会社 | (z)−1−フェニル−1−ジエチルアミノカルボニル−2−アミノメチルシクロプロパン塩酸塩の製造方法 |
ZA200700599B (en) | 2004-06-25 | 2008-09-25 | Sumitomo Chemical Co | Method for producing (Z)-1-phenyl-1-diethylamino-carbonyl-2-hydroxymethyl cyclopropane |
JP4828863B2 (ja) | 2005-01-28 | 2011-11-30 | 住友化学株式会社 | (z)−1−フェニル−1−(n,n−ジエチルアミノカルボニル)−2−フタルイミドメチルシクロプロパンの製造方法 |
KR100772244B1 (ko) * | 2005-07-20 | 2007-11-01 | 안국약품 주식회사 | 밀나시프란염산염의 제조방법 |
KR20140068261A (ko) | 2009-12-04 | 2014-06-05 | 인터디지탈 패튼 홀딩스, 인크 | 하이브리드 네트워크에서 통합 게이트웨이에 대한 확장형 로컬 ip 액세스 |
-
2009
- 2009-01-29 FR FR0950552A patent/FR2941454B1/fr active Active
-
2010
- 2010-01-25 TW TW099101933A patent/TWI455911B/zh active
- 2010-01-29 KR KR1020117019602A patent/KR101719011B1/ko active IP Right Grant
- 2010-01-29 GE GEAP201012350A patent/GEP20135903B/en unknown
- 2010-01-29 AU AU2010209686A patent/AU2010209686B2/en active Active
- 2010-01-29 WO PCT/EP2010/051045 patent/WO2010086394A1/en active Application Filing
- 2010-01-29 CN CN2010800057211A patent/CN102300840A/zh active Pending
- 2010-01-29 RU RU2011135326/04A patent/RU2521342C2/ru active
- 2010-01-29 EP EP10701538.0A patent/EP2391599B1/en active Active
- 2010-01-29 CN CN201910530393.XA patent/CN110204455A/zh active Pending
- 2010-01-29 UA UAA201110404A patent/UA104884C2/uk unknown
- 2010-01-29 MX MX2011007846A patent/MX2011007846A/es active IP Right Grant
- 2010-01-29 BR BRPI1007404A patent/BRPI1007404B8/pt active IP Right Grant
- 2010-01-29 ES ES10701538.0T patent/ES2472695T3/es active Active
- 2010-01-29 US US13/146,361 patent/US8604241B2/en active Active
- 2010-01-29 NZ NZ594291A patent/NZ594291A/xx unknown
- 2010-01-29 AR ARP100100245A patent/AR077526A1/es not_active Application Discontinuation
- 2010-01-29 MA MA34052A patent/MA33025B1/fr unknown
- 2010-01-29 CA CA2750488A patent/CA2750488C/en active Active
- 2010-01-29 JP JP2011546850A patent/JP5646509B2/ja active Active
- 2010-01-29 PL PL10701538T patent/PL2391599T3/pl unknown
-
2011
- 2011-07-21 IL IL214241A patent/IL214241A/en active IP Right Grant
- 2011-07-22 ZA ZA2011/05414A patent/ZA201105414B/en unknown
- 2011-07-22 TN TN2011000363A patent/TN2011000363A1/fr unknown
-
2019
- 2019-06-04 AR ARP190101513A patent/AR115475A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5646509B2 (ja) | (1s,2r)−ミルナシプランの合成方法 | |
MX2009001019A (es) | Proceso para preparacion de ciclopropilaminas opticamente activas. | |
KR20070087596A (ko) | (s)-(+)-3-(아미노메틸)-5-메틸헥산산의 비대칭 합성 | |
JP7339946B2 (ja) | 2-(5-メトキシイソクロマン-1-イル)-4,5-ジヒドロ-1h-イミダゾールおよびその硫酸水素塩の製造方法 | |
WO2006125964A1 (en) | A process for the dynamic resolution of (substituted) (r) - or (s) -mandelic acid | |
JP2005247828A (ja) | 光学的に活性であるセリン誘導体の製造方法 | |
EP3653607B1 (en) | Process for the preparation of enantiomerically enriched 3-aminopiperidine | |
WO2016037588A2 (zh) | 用于合成抗艾滋病药物增强剂cobicistat的新中间体 | |
WO2014009964A1 (en) | Process for enantiomeric enrichment of 2 ', 6 ' - pipecoloxylidide | |
EP2805936A1 (en) | Process for preparing levomilnacipran HCL | |
JPH06116217A (ja) | (±)−シス−4−アミノシクロペント−2−エンカルボン酸誘導体の光学分割法 | |
JP2010037206A (ja) | 光学活性なo−メチルセリンまたはその塩の製造法 | |
JP2010513531A (ja) | 1−アミノ、3−置換フェニルシクロペンタンカルボン酸エステルの個々の立体異性体の製造および単離方法 | |
EP3105214A1 (en) | A new method for producing nebivolol hydrochloride of high purity | |
CN111333552B (zh) | β-苯并氨基酸类化合物的合成方法 | |
WO2017019791A1 (en) | Synthesis of (s)-pregabalin | |
JP2010530397A (ja) | アミド形成の改善方法 | |
EP0411074A1 (en) | Resolution process | |
JP4126921B2 (ja) | 光学活性なβ−フェニルアラニン誘導体の製造方法 | |
JP2007277224A (ja) | トランス−4−アミノ−1−メチルシクロヘキサノール類の製造方法 | |
JP3828197B2 (ja) | 光学活性3−(p−メトキシフェニル)グリシッド酸アルカリ金属塩の製造法 | |
Xue et al. | An improved and efficient process for the scalable preparation of optically pure trans-2-aminocyclohexanols | |
JP2000026384A (ja) | 光学活性4―アミノ―3―(ジハロゲノ置換フェニル)酪酸の製造方法 | |
JP2002241318A (ja) | 光学活性な2−アミノ−1−アセナフテノール誘導体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130108 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140328 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140819 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140917 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141010 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141105 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5646509 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |